AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05621174
Drug: Dexamfetamine
RxNorm normalized name: Dexamfetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tentin
Trial: NCT06350097
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet .
Trial: NCT06350097
Drug: Datopotamab Deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Trial: NCT05030493
Drug: mFOLFOX6 + panitumumab combination therapy
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Trial: NCT05030493
Drug: mFOLFOX6 + bevacizumab combination therapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Trial: NCT05900895
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
Trial: NCT00057395
Drug: Aroplatin (Liposomal NDDP, L-NDDP)
RxNorm normalized name: Carboplatin
DrugBank: Aroplatin (DB17319)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04895098
Drug: statin and ezetimibe combination therapy
RxNorm normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
Trial: NCT05100069
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib Tablets
Trial: NCT05522673
Drug: 11(R)-rolipram
RxNorm normalized name: R
DrugBank: Rolipram (DB01954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IV followed by PET scanning
Trial: NCT05635487
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811
Trial: NCT05635487
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib
Trial: NCT06379867
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 g, Oral administration with 240 mL
Trial: NCT06446206
Drug: Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
Trial: NCT06252857
Drug: Imiquimod Topical
RxNorm normalized name: imiquimod topical
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
Trial: NCT04904965
Drug: Propofol Group 1
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kg/hr per 10 min
Trial: NCT04904965
Drug: Propofol Group 2
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 4.0 mg/kg/hr per 10 min
Trial: NCT04904965
Drug: Propofol Group 3
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 6.0 mg/kg/hr per 10 min
Trial: NCT04904965
Drug: Propofol Group 4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 8.0 mg/kg/hr per 10 min
Trial: NCT05719051
Drug: Albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusion was administrated according to the standard clinical practice
Trial: NCT05366192
Drug: Nirmatrelvir and ritonavir stage 1
RxNorm normalized name: nirmatrelvir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
Trial: NCT05366192
Drug: Nirmatrelvir and ritonavir stage 2
RxNorm normalized name: nirmatrelvir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
Trial: NCT05341570
Drug: BPI-21668
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive BPI-21668 until disease progression
Trial: NCT00347035
Drug: brimonidine
RxNorm normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04603391
Drug: dl-Methylphenidate plus Cannabidiol
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
Trial: NCT04603391
Drug: dl-Methylphenidate plus Cannabidiol Placebo solution
RxNorm normalized name: cannabidiol Oral Solution
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
Trial: NCT05896046
Drug: SHR-1701
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
Trial: NCT00011479
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05052528
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05001061
Drug: Misoprostol Pill
RxNorm normalized name: misoprostol Pill
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
Trial: NCT04965129
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
Trial: NCT04944888
Drug: Eliglustat
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
Trial: NCT04944888
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immune checkpoint inhibitor (physician decided).
Trial: NCT05536193
Drug: Topical Metformin Emulgel and salicylic acid
RxNorm normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid
Trial: NCT04870827
Drug: 13N Amonia
RxNorm normalized name: ammonia (13N)
DrugBank: Ammonia (DB11118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered during PET/CT scans
Trial: NCT06581315
Drug: Donafenib
RxNorm normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donafenib 100 mg twice daily (BID)
Trial: NCT04782804
Drug: PD-1 Antibody（Tislelizumab）
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
Trial: NCT05632224
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug is given 1 hour before the start of the surgery
Trial: NCT05632224
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug is given 10 minutes before the patients's extubation
Trial: NCT04923620
Drug: cetuximab+mFOLFOX6
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
Trial: NCT04824417
Drug: Itraconazole 200 mg
RxNorm normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT04824417
Drug: Voriconazole 200mg
RxNorm normalized name: VORICONAZOLE 200MG TAB
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT04861558
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of 360 mg/m2
Trial: NCT04861558
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection of 460 mg/m2
Trial: NCT05929885
Drug: Low Dose OXIRI (LD-OXIRI)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status.
Trial: NCT05897112
Drug: Group A received cryotherpay
RxNorm normalized name: meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
Trial: NCT05897112
Drug: Group B received 10% Potassium Hydroxide Solution
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
Trial: NCT06517862
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
Trial: NCT04950205
Drug: Sevoflurane inhalant product
RxNorm normalized name: sevoflurane Inhalant Product
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
Trial: NCT06391944
Drug: JMT101 Injection
RxNorm normalized name: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
DrugBank: Becotatug (DB19069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
Trial: NCT06391944
Drug: Osimertinib tablet
RxNorm normalized name: Osimertinib Tablets
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib 80 or 160mg po everyday
Trial: NCT00002392
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05010629
Drug: 9-ING-41
RxNorm normalized name: ING-1
DrugBank: ING-1 (DB05831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05010629
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05344027
Drug: Mitotane
RxNorm normalized name: Mitotane
DrugBank: Mitotane (DB00648)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
Trial: NCT05024747
Drug: NicoDerm CQ (Alza)
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
Trial: NCT05663242
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Trial: NCT05663242
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
Trial: NCT06281405
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w
Trial: NCT06356948
Drug: Tranexamic Acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug administration
Trial: NCT04702048
Drug: Aflibercept Injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
Trial: NCT04702048
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
Trial: NCT04796428
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
Trial: NCT04796428
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used.
Trial: NCT04796428
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used.
Trial: NCT06278896
Drug: Cessation of antibiotics
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
Trial: NCT05675098
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This medication is a psychostimulant medication and is usually prescribed for individuals with Attention-Deficit/Hyperactivity Disorder to manage ADHD behavioral symptoms
Trial: NCT05693090
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05693090
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration
Trial: NCT05137730
Drug: rhPTH(1-84)
RxNorm normalized name: rhPTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Trial: NCT05675098
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This medication is a Central Nervous System stimulant and is usually used to treat neurological conditions, including Narcolepsy
Trial: NCT05363670
Drug: ARS-1
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARS-1
Trial: NCT05363670
Drug: Albuterol MDI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mcg
Trial: NCT04861948
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT04861948
Drug: Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT04861948
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous
Trial: NCT04861948
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT04861948
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous
Trial: NCT03003195
Drug: P10s-PADRE
RxNorm normalized name: gamma4 heavy chain Homo sapiens (1-442) [VH (Homo sapiens IGHV3-23*04 (94.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115)-Homo sapiens IGHG4*01, G4v5 h P10, nG4m(a) CH2 L92 (CH1(116-213), hinge 1-12 S10>P (223) (214-225), CH2
DrugBank: Mevonlerbart (DB19416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
Trial: NCT05053126
Drug: Pregabalin 300mg
RxNorm normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participant will receive an oral dose of pregabalin 300 mg
Trial: NCT05053126
Drug: pregabalin 450 mg
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participant will receive an oral dose of pregabalin 450 mg
Trial: NCT05053126
Drug: Pregabalin 300 mg with oxycodone 20 mg
RxNorm normalized name: pregabalin 300 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
Trial: NCT05053126
Drug: pregabalin 450 mg with oxycodone 20 mg
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
Trial: NCT05053126
Drug: oxycodone 20 mg
RxNorm normalized name: oxycodone 20 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant will receive an oral dose of oxycodone 20 mg
Trial: NCT06472388
Drug: Everolimus 5 MG
RxNorm normalized name: everolimus 5 MG
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral everolimus 5 mg/daily
Trial: NCT04928495
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg / day for ten days
Trial: NCT04928495
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 1800 mg / day for ten days.
Trial: NCT04928495
Drug: NAC + Bromhexine (BMX)
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC + Bromhexine (BMX) 32 mg / day for ten days.
Trial: NCT05009030
Drug: COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
Trial: NCT01017822
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes